Zensar TechnologiesQ1 FY25

Zensar Technologies Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹528P/E: 15.0Market Cap: ₹12.0K CrSector: IT - Software

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4
  • Zensar Technologies is positive about growth across all verticals, with sequential growth reported in two consecutive quarters.
  • For FY '25, the company expects continued momentum in its verticals including Telecom, BFSI, Healthcare, and Life Sciences.
  • There is an aspiration to be in line with industry growth this year and aim for leadership in growth rates next year.
  • The large deal pipeline is improving, with anticipation to convert 1-2 large deals in FY '25.
  • Despite some headwinds like furloughs and bankruptcy impacts, the company remains cautiously optimistic about maintaining around 4% sequential revenue growth.
  • Sector-wise, BFSI is showing strong and sustained recovery with positive momentum; TMT had some softness recently but is expected to stabilize.
  • South Africa remains a strategic geography with good volume growth despite currency fluctuations.
  • Overall, the focus on cross-selling, capability building, and strategic acquisitions (e.g., BridgeView Life Sciences) supports growth expectations.

See what Zensar Technologies management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or future fundraising through debt or equity in the provided transcript from the Zensar Technologies Q1 FY'25 earnings call.
  • The management focuses mainly on operational performance, growth by verticals, margin outlook, and acquisitions like BridgeView Life Sciences.
  • The company reported strong financial health with increased cash and cash equivalents ($280.9 million) and improved DSOs.
  • There is no indication or discussion related to plans for raising funds via debt or equity in the available content.

See what Zensar Technologies management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Zensar Technologies has made a strategic investment by acquiring BridgeView Life Sciences, a Pennsylvania-based technology and consulting solutions company specializing in the pharmaceutical commercial segment.
  • This acquisition enhances Zensar's focus on the Healthcare and Life Sciences vertical and strengthens their end-to-end pharmaceutical commercial quality and regulatory capabilities.
  • The company continues to invest in key verticals such as BFSI, Healthcare, and Life Sciences, focusing on strategic areas that offer quick returns and align with their growth goals.
  • There is an emphasis on talent transformation and capability building, including investments in training, cross-training, and onboarding fresh talent to support business growth.
  • No specific future capex numbers were disclosed in the provided transcript, but management indicated ongoing investments for growth across strategic geographies like South Africa and in areas such as AI, GenAI, Data Engineering, and Cloud services.

Track Zensar Technologies — get its next earnings analysis in your feed

How does Zensar Technologies rank vs peers in IT - Software?

Pro feature
ThisZensar Technologies
Rev 4Mar 3

How does Zensar Technologies rank in IT - Software?

Compare Zensar Technologies against every IT - Software company (Q1 FY25) on revenue, margins and earnings-call signals.

View IT - Software leaderboard →

Others in IT - Software this season

  • Virtual Galaxy (Q2 FY27)

    Q2 FY27 revenue from operations was ₹64.2 crore, up 59% sequentially (Page 4). Key investor presentation takeaways from Virtual Galaxy Infotech Ltd's Q2 FY27 in

  • California Software Company (Q2 FY27)

    For the quarter ended 30 September 2026, California Software Company Limited reported revenue from operations of ₹263.11 lakhs. Key results statement takeaways

  • Delaplex (Q2 FY27)

    Revenue from operations (Consolidated) for the half year ended September 30, 2026: ₹4,135.42 Lakhs, up from ₹3,717.75 Lakhs for the half year ended September…

  • Innovana Thinklabs (Q2 FY27)

    1,188.41 Lacs (~36.3% increase) . Key results statement takeaways from Innovana Thinklabs Ltd's Q2 FY27 results statement — and how it ranks against sector peer

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →